menu

Loading...

EDAP Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

4.280

Open

4.220

VWAP

4.04

Vol

76.90K

Mkt Cap

153.31M

Low

3.740

Amount

310.68K

EV/EBITDA(TTM)

--

Total Shares

37.39M

EV

158.11M

EV/OCF(TTM)

--

P/S(TTM)

2.19

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

Show More

Events Timeline

(ET)

2026-02-12

07:40:00

EDAP TMS Appoints David Horn to Board of Directors

2026-01-12 (ET)

2026-01-12

07:40:00

Focal One CEO: Strong Finish to 2025, HIFU Revenue Exceeds Half of Annual Revenue

2026-01-12

07:40:00

FY26 Combined Non-Core Business Revenue Expected Between $22.0M and $26.0M

2025-11-20 (ET)

2025-11-20

07:33:12

EDAP TMS Secures FDA 510(k) Approval for Focal One Robotic HIFU

2025-11-06 (ET)

2025-11-06

07:48:03

EDAP TMS announces Q3 earnings per share of 16 cents, compared to a loss of 19 cents in the previous year.

2025-10-20 (ET)

2025-10-20

08:42:54

EDAP TMS Secures €36 Million Credit Facility from EIB

2025-09-30 (ET)

2025-09-30

07:16:26

EDAP TMS: Focal One Robotic HIFU Highlighted on 'Health Uncensored with Dr. Drew'

2025-09-08 (ET)

2025-09-08

07:11:17

EDAP TMS Secures HIFU Reimbursement for Prostate Cancer Treatment in France

2025-08-28 (ET)

2025-08-28

07:05:19

EDAP TMS announces Q2 earnings per share of 17 cents, compared to 18 cents in the same period last year.

2025-08-26 (ET)

2025-08-26

07:07:34

EDAP TMS Secures Letter of Intent for €36 Million Credit Facility

News

Newsfilter

02-12Newsfilter

EDAP Appoints David Horn to Board of Directors

Globenewswire

01-12Globenewswire

EDAP Reports Record 2025 HIFU Revenue, Issues 2026 Guidance for 36%-38% Growth

Newsfilter

01-12Newsfilter

EDAP Reports Record 2025 HIFU Revenue, Issues 2026 Guidance for 36%-38% Growth

Newsfilter

2025-11-24Newsfilter

EDAP Receives FDA 510(k) Clearance for Enhanced Focal One HIFU System

NASDAQ.COM

2025-10-29NASDAQ.COM

GNTA, BBIO, AMRN Surge in After-Hours Trading: Major Biotech Factors Fueling Stock Increases

Newsfilter

2025-10-17Newsfilter

Natural Killer Cell Treatments Drive $254B Shift in Immunotherapy Market

2 Analyst Rating

Wall Street analysts forecast EDAP stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

8.25

High

14.00

Current: 0.000

Low

2.50

Averages

8.25

High

14.00

H.C. Wainwright

H.C. Wainwright

Buy

downgrade

$19 -> $14

AI Analysis

2025-05-16

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$19 -> $14

AI Analysis

2025-05-16

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on EDAP TMS to $14 from $19 and keeps a Buy rating on the shares following the Q1 report. The firm accounts for management's de-emphasizing the noncore businesses.

Piper Sandler

Overweight -> Neutral

downgrade

2025-05-15

Reason

Piper Sandler

Price Target

2025-05-15

downgrade

Overweight -> Neutral

Reason

Piper Sandler downgraded EDAP TMS to Neutral from Overweight with a price target of $1.50, down from $4.50. The downgrade is "less about 1Q results," which were "fine even if not spectacular," and more about the operational and financial challenges the firm sees over the next year, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EDAP

Unlock Now

Valuation Metrics

The current forward P/E ratio for Edap Tms SA (EDAP.O) is -5.14, compared to its 5-year average forward P/E of -29.17. For a more detailed relative valuation and DCF analysis to assess Edap Tms SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-29.17

Current PE

-5.14

Overvalued PE

74.54

Undervalued PE

-132.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-74.68

Current EV/EBITDA

-6.29

Overvalued EV/EBITDA

117.91

Undervalued EV/EBITDA

-267.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.23

Current PS

1.80

Overvalued PS

4.75

Undervalued PS

1.71

Financials

AI Analysis

Annual

Quarterly

Whales Holding EDAP

Soleus Capital Management, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Edap Tms SA (EDAP) stock price today?

The current price of EDAP is 4.1 USD — it has decreased -6.18

What is Edap Tms SA (EDAP)'s business?

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

What is the price predicton of EDAP Stock?

Wall Street analysts forecast EDAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDAP is8.25 USD with a low forecast of 2.50 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Edap Tms SA (EDAP)'s revenue for the last quarter?

Edap Tms SA revenue for the last quarter amounts to 13.88M USD, increased 5.96

What is Edap Tms SA (EDAP)'s earnings per share (EPS) for the last quarter?

Edap Tms SA. EPS for the last quarter amounts to -0.13 USD, decreased -23.53

How many employees does Edap Tms SA (EDAP). have?

Edap Tms SA (EDAP) has 310 emplpoyees as of March 03 2026.

What is Edap Tms SA (EDAP) market cap?

Today EDAP has the market capitalization of 153.31M USD.